This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
SAN FRANCISCO — For patients with hepatitis C who are receiving opioid substitutes, the once-daily single-tablet combination of sofosbuvir plus ledipasvir (Harvoni Gilead Sciences) is well tolerated and effective, according to an analysis of data from the phase 3 ION studies.
“As long as you anticipate drug interactions, opiate therapy should not prevent treatment,” said Nancy Reau, MD, from Rush University Medical Center in Chicago, who presented the finding here at the International Conference on Viral Hepatitis 2016.
A disproportionate number of people who inject drugs are infected with hepatitis C. Treatment protects the livers of infected people and also prevents transmission of the disease, Dr Reau told Medscape Medical News.